ライフサイエンスコーパス: prostatic hyperplasia

1 uced BSM hypertrophy, and in men with benign prostatic hyperplasia.

2 eve bladder outlet obstruction due to benign prostatic hyperplasia.

3 other modalities for the treatment of benign prostatic hyperplasia.

4 ther surgical treatments for men with benign prostatic hyperplasia.

5 ation may be associated with LUTS and benign prostatic hyperplasia.

6 al interaction of prostate cancer and benign prostatic hyperplasia.

7 as a therapeutic for the treatment of benign prostatic hyperplasia.

8 wer urinary tract symptoms related to benign prostatic hyperplasia.

9 and ARI was used to treat symptomatic benign prostatic hyperplasia.

10 y related to prostatic enlargement or benign prostatic hyperplasia.

11 ocker prescribed for the treatment of benign prostatic hyperplasia.

12 t expressed in normal prostate nor in benign prostatic hyperplasia.

13 lay a critical role in development of benign prostatic hyperplasia.

14 ract symptoms are often attributed to benign prostatic hyperplasia.

15 adder outlet obstruction secondary to benign prostatic hyperplasia.

16 ove symptoms or objective measures of benign prostatic hyperplasia.

17 an nondaily NSAID users of developing benign prostatic hyperplasia.

18 rigorously analyzed interventions for benign prostatic hyperplasia.

19 te over other surgical treatments for benign prostatic hyperplasia.

20 e may prevent or delay development of benign prostatic hyperplasia.

21 other surgical therapies for men with benign prostatic hyperplasia.

22 potential role in the pathogenesis of benign prostatic hyperplasia.

23 ent of endometriosis, leiomyomas, and benign prostatic hyperplasia.

24 ropriate management of a patient with benign prostatic hyperplasia.

25 or for prostate cancer among men with benign prostatic hyperplasia.

26 a patient with symptoms suggestive of benign prostatic hyperplasia.

27 dysfunction, neurological factors and benign prostatic hyperplasia.

28 ncluding prostatic adenocarcinoma and benign prostatic hyperplasia.

29 asures of the clinical progression of benign prostatic hyperplasia.

30 useful for the analyses of early changes in prostatic hyperplasia.

31 n the etiology of prostate cancer and benign prostatic hyperplasia.

32 mally invasive surgical therapies for benign prostatic hyperplasia.

33 eatment for most men with symptomatic benign prostatic hyperplasia.

34 ficacious in reducing the symptoms of benign prostatic hyperplasia.

35 er in the context of the aetiology of benign prostatic hyperplasia.

36 th or without obstructive symptoms of benign prostatic hyperplasia.

37 ast year in the medical management of benign prostatic hyperplasia.

38 ruction thought to be associated with benign prostatic hyperplasia.

39 it pertains to the pathophysiology of benign prostatic hyperplasia.

40 my became a widely used treatment for benign prostatic hyperplasia.

41 ndividuals and individuals with nonmalignant prostatic hyperplasia.

42 nsition zone tissue of prostates with benign prostatic hyperplasia.

43 f BPSA-specific mAbs for the study of benign prostatic hyperplasia.

44 n, and to develop novel therapies for benign prostatic hyperplasia.

45 leviating urethral obstruction due to benign prostatic hyperplasia.

46 es such as myocardial hypertrophy and benign prostatic hyperplasia.

47 nation of both drugs in 1229 men with benign prostatic hyperplasia.

48 will have utility in the treatment of benign prostatic hyperplasia.

49 spatial extent of prostate cancer and benign prostatic hyperplasia.

50 ety of PCA specimens, cell lines, and benign prostatic hyperplasia.

51 r urinary tract symptoms secondary to benign prostatic hyperplasia.

52 to differentiate prostate cancer and benign prostatic hyperplasia.

53 ) are widely used in the treatment of benign prostatic hyperplasia.

54 d a testosterone-induced rat model of benign prostatic hyperplasia.

55 ansurethral resection of prostate for benign prostatic hyperplasia.

56 deleted in human prostate cancer, results in prostatic hyperplasia.

57 stromal nodules associated with human benign prostatic hyperplasia.

58 one cancers and glandular and stromal benign prostatic hyperplasia.

59 n ATF3 knockout mice that is associated with prostatic hyperplasia.

60 ety, and long-term results of PAE for benign prostatic hyperplasia.

61 and improved the outcomes related to benign prostatic hyperplasia.

62 n regions of histologically confirmed benign prostatic hyperplasia (0.61 +/- 0.21 [standard deviation

63 higher levels of IGF-1 and stimulate benign prostatic hyperplasia-1 cellular proliferation.

64 the prostate (PCA), 15 patients with benign prostatic hyperplasia, 15 normal male subjects, and 5 fe

65 te loss of NKX3.1 expression in 5% of benign prostatic hyperplasias, 20% of high-grade prostatic intr

66 significantly different from that of benign prostatic hyperplasia (4.8 +/- 2.01 [range, 1.8-8.8]).

67 mic patients were more likely to have benign prostatic hyperplasia (56% vs 19%; P = .04), a history o

68 d positively in 0 of 12 (0%) cases of benign prostatic hyperplasia, 57 of 63 (90.5%) primary adenocar

69 rostate cancer, age at randomization, benign prostatic hyperplasia, age and stage at diagnosis, heigh

70 ently misdiagnosed as prostatitis and benign prostatic hyperplasia among men.

71 eductase inhibitors are used to treat benign prostatic hyperplasia and androgenic alopecia, but the r

72 Urinary complications resulting from benign prostatic hyperplasia and bladder outlet obstruction con

73 Patients with symptomatic benign prostatic hyperplasia and cataracts requiring a uroselec

74 Nkx3.1 mutant mice display prostatic hyperplasia and dysplasia and are used as a mo

75 bolizing activity, resulted in age-dependent prostatic hyperplasia and enlargement of the prostate.

76 ed in relation to the pathogenesis of benign prostatic hyperplasia and future directions for research

77 city needed to differentiate PCa from benign prostatic hyperplasia and have high false positive rates

78 ors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding protein

79 extensively used for the treatment of benign prostatic hyperplasia and in experimental settings for p

80 late in predicting the progression of benign prostatic hyperplasia and in recent years increased inte

81 rin and quiescin Q6, are highly expressed in prostatic hyperplasia and intraepithelial neoplasia (PIN

82 he United States for the treatment of benign prostatic hyperplasia and is commonly recommended as an

83 failure, or as definitive therapy for benign prostatic hyperplasia and its associated problems is sti

84 - for the prevention or treatment of benign prostatic hyperplasia and lower urinary tract symptoms h

85 with significantly increased risks of benign prostatic hyperplasia and lower urinary tract symptoms i

86 atives within the context of standard benign prostatic hyperplasia and lower urinary tract symptoms t

87 t have been used for the treatment of benign prostatic hyperplasia and lower urinary tract symptoms.

88 y for the prevention and treatment of benign prostatic hyperplasia and lower urinary tract symptoms.

89 ) is associated with prostate cancer, benign prostatic hyperplasia and male infertility.

90 d progression of prostatic diseases, such as prostatic hyperplasia and preneoplastic lesions.

91 issue, with substantial expression in benign prostatic hyperplasia and prominent expression in neopla

92 Both benign prostatic hyperplasia and prostate cancer are common con

93 EMT processes have been implicated in benign prostatic hyperplasia and prostate cancer progression.

94 sly linked to the development of both benign prostatic hyperplasia and prostate cancer.

95 tion and/or altered susceptibility to benign prostatic hyperplasia and prostate cancer.

96 e evidence for an association between benign prostatic hyperplasia and serum IGF-I.

97 problems presenting to urologists are benign prostatic hyperplasia and sexual dysfunction, with an in

98 men with lower urinary tract symptoms/benign prostatic hyperplasia and the associated risk of acute u

99 apy on the risk of surgery related to benign prostatic hyperplasia and the predictors of disease prog

100 t have been used for the treatment of benign prostatic hyperplasia and voiding dysfunction.

101 may play a role in the development of benign prostatic hyperplasia and/or lower urinary tract symptom

102 perplastic conditions, including mammary and prostatic hyperplasia, and could also be involved in the

103 erent group after adjustment for age, benign prostatic hyperplasia, and family history.

104 age, race/ethnicity, smoking history, benign prostatic hyperplasia, and family history.

105 tissues derived from normal prostate, benign prostatic hyperplasia, and prostate carcinomas, IL-11Ral

106 uminal epithelium of normal prostate, benign prostatic hyperplasia, and prostatic intraepithelial neo

107 es of 5 alpha-reductase inhibitors in benign prostatic hyperplasia, and these may expand further if c

108 Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history o

109 d evaluated medications used to treat benign prostatic hyperplasia, anti-inflammatory drugs, antibiot

110 Prostatic hyperplasia appeared in the lateral and ventra

111 Prostate cancer and benign prostatic hyperplasia are common genitourinary diseases

112 that lower urinary tract symptoms and benign prostatic hyperplasia are definitely related to erectile

113 men with lower urinary tract symptoms/benign prostatic hyperplasia are few and far between, but preli

114 act symptoms that are consistent with benign prostatic hyperplasia are not more likely to harbor pros

115 s, commonly used for the treatment of benign prostatic hyperplasia, are associated with prostate canc

116 In benign prostatic hyperplasia, basal cells and areas of basal ce

117 rugs has been considered hazardous in benign prostatic hyperplasia because of concerns that they may

118 ity for distinguishing early PCa from benign prostatic hyperplasia, because both PCa and benign prost

119 le KGF expression was not detected in benign prostatic hyperplasia (BPH) (n = 6).

120 s with potential for the treatment of benign prostatic hyperplasia (BPH) (see part 1 of this series).

121 aluated in relation to development of benign prostatic hyperplasia (BPH) among 29,386 members of the

122 ence and progression of components of benign prostatic hyperplasia (BPH) and a clinical outcome of BP

123 Benign prostatic hyperplasia (BPH) and associated lower urinary

124 Benign prostatic hyperplasia (BPH) and associated lower urinary

125 rs (5-ARIs) are approved for treating benign prostatic hyperplasia (BPH) and have been found to reduc

126 r outlet obstruction (PBOO) caused by benign prostatic hyperplasia (BPH) and in animal models of PBOO

127 components of metabolic syndrome and benign prostatic hyperplasia (BPH) and lower urinary tract symp

128 ly influence the risks of symptomatic benign prostatic hyperplasia (BPH) and lower urinary tract symp

129 play prominent roles in the cause of benign prostatic hyperplasia (BPH) and lower urinary tract symp

130 Benign prostatic hyperplasia (BPH) and prostate adenocarcinoma

131 d the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer risk in

132 eriodontitis and prostate diseases of benign prostatic hyperplasia (BPH) and prostatitis is uncertain

133 high-grade clinical CaP (compared to benign prostatic hyperplasia (BPH) and well-differentiated tumo

134 Chronic prostatitis (CPr) and benign prostatic hyperplasia (BPH) are complex inflammatory con

135 Although surrogate measures of benign prostatic hyperplasia (BPH) are often used in epidemiolo

136 Benign prostatic hyperplasia (BPH) as the main cause of lower u

137 n seems to modify the pathogenesis of benign prostatic hyperplasia (BPH) effect symptomology in men s

138 scriminate prostatic inflammation and benign prostatic hyperplasia (BPH) from prostate cancer, and to

139 The understanding and therapy of benign prostatic hyperplasia (BPH) has become more complex rece

140 ned dietary risk factors for incident benign prostatic hyperplasia (BPH) in 4,770 Prostate Cancer Pre

141 Benign prostatic hyperplasia (BPH) in older men can cause lower

142 Benign prostatic hyperplasia (BPH) is a common cause of morbidi

143 Benign prostatic hyperplasia (BPH) is a common disease of older

144 urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) is a common medical problem

145 Benign Prostatic Hyperplasia (BPH) is a complex condition leadi

146 tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) is a condition that commonly

147 Benign prostatic hyperplasia (BPH) is a disease of unknown etio

148 Background Benign prostatic hyperplasia (BPH) is a disease that affects mi

149 Lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) is a highly prevalent chroni

150 Benign prostatic hyperplasia (BPH) is a pathologic proliferatio

151 Benign prostatic hyperplasia (BPH) is a prevalent age-related c

152 Benign prostatic hyperplasia (BPH) is a progressive age-related

153 Benign prostatic hyperplasia (BPH) is an extremely common disea

154 Benign prostatic hyperplasia (BPH) is characterized by increase

155 The etiology of benign prostatic hyperplasia (BPH) is multifactorial, and chron

156 Benign prostatic hyperplasia (BPH) is prevalent in old men and

157 interest (VOIs) for prostate tumors, benign prostatic hyperplasia (BPH) nodules, prostatitis, and he

158 y 2019, 102 patients with symptoms of benign prostatic hyperplasia (BPH) not candidates for surgery o

159 ct of different treatment options for benign prostatic hyperplasia (BPH) on sexual function or dysfun

160 Benign prostatic hyperplasia (BPH) results in a significant pub

161 nucleus of PCa samples; in contrast, benign prostatic hyperplasia (BPH) samples presented strong nuc

162 ncer cell lines, prostate cancer, and benign prostatic hyperplasia (BPH) tissues samples using the bi

163 of primary human prostate cancer and benign prostatic hyperplasia (BPH) using cDNA microarrays consi

164 Of the 35 benign prostatic hyperplasia (BPH), 25 (71.4%) specimens were u

165 Benign prostatic hyperplasia (BPH), a nonmalignant enlargement

166 ent pharmacotherapies for symptomatic benign prostatic hyperplasia (BPH), an androgen receptor-driven

167 in the development and progression of benign prostatic hyperplasia (BPH), but the underlying mechanis

168 ety is used in the initial therapy of benign prostatic hyperplasia (BPH), globally.

169 rinary tract symptoms associated with benign prostatic hyperplasia (BPH), the etiology of which is no

170 g (NSAID) use and risk of symptomatic benign prostatic hyperplasia (BPH), using data from 4,735 men w

171 um steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the placebo

172 atory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo

173 econd most common male neoplasia, and benign prostatic hyperplasia (BPH), which affects approximately

174 7 overexpression in BSM from men with benign prostatic hyperplasia (BPH)-induced bladder hypertrophy

175 on (TAE) as a potential treatment for benign prostatic hyperplasia (BPH).

176 e, have been used in the treatment of benign prostatic hyperplasia (BPH).

177 l known approach to the management of benign prostatic hyperplasia (BPH).

178 ferentiation might reduce the risk of benign prostatic hyperplasia (BPH).

179 ncy and incontinence in patients with benign prostatic hyperplasia (BPH).

180 cells derived from normal tissues or benign prostatic hyperplasia (BPH).

181 e used to treat both hypertension and benign prostatic hyperplasia (BPH).

182 ity for distinguishing early PCa from benign prostatic hyperplasia (BPH).

183 agonists as a potential treatment for benign prostatic hyperplasia (BPH).

184 the growth of prostatic carcinoma and benign prostatic hyperplasia (BPH).

185 has been suggested as an etiology for benign prostatic hyperplasia (BPH).

186 ity for distinguishing early PCa from benign prostatic hyperplasia (BPH).

187 r levels than cells representative of benign prostatic hyperplasia (BPH).

188 utlet procedures for the treatment of benign prostatic hyperplasia (BPH).

189 n the pathogenesis and progression of benign prostatic hyperplasia (BPH).

190 new viewpoints of hormonal control of benign prostatic hyperplasia (BPH).

191 urinary tract symptoms attributed to benign prostatic hyperplasia (BPH); however, recent clinical tr

192 as the gold standard for treatment of benign prostatic hyperplasia (BPH); however, there has been sig

193 ph node metastases (LNMs; n = 8), and benign prostatic hyperplasia (BPH; n = 6) with the use of IHC.

194 noncancerous disease categories (eg, benign prostatic hyperplasia [BPH], prostatic intraepithelial n

195 xpression of transformed [tumorigenic benign prostatic hyperplasia (BPH1)(CAFTD)] and parental (nontu

196 ls in normal prostatic epithelium and benign prostatic hyperplasia but significantly increased in pro

197 improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benef

198 hniques in diagnosis and treatment of benign prostatic hyperplasia by reviewing the most recent publi

199 Men with benign prostatic hyperplasia can be treated with alpha 1-adrene

200 Prostatic hyperplasia caused by both 15-LOX2 and 15-LOX2

201 Overactive bladder and benign prostatic hyperplasia commonly cause lower urinary tract

202 ld standard for surgical treatment of benign prostatic hyperplasia continues to be transurethral rese

203 Benign prostatic hyperplasia contributes to these mechanical st

204 ur simulations show that a history of benign prostatic hyperplasia creates mechanical stress fields i

205 as the need for invasive treatment of benign prostatic hyperplasia, development of a clinical prostat

206 role in normal prostate development, benign prostatic hyperplasia, established prostate cancer, and

207 in studies of dutasteride therapy for benign prostatic hyperplasia, except that in our study, as comp

208 tive for the treatment of symptomatic benign prostatic hyperplasia for men with prostates of any size

209 ection of the prostate procedures for benign prostatic hyperplasia from 1983 to 2013 were collected.

210 ls in the serum may help discriminate benign prostatic hyperplasia from early prostate cancer.

211 antigen marker to better discriminate benign prostatic hyperplasia from early prostate cancer.

212 terest in lasers for the treatment of benign prostatic hyperplasia has been rekindled.

213 much of the available information on benign prostatic hyperplasia has come from randomized controlle

214 to benign prostatic obstruction from benign prostatic hyperplasia has proven to be an effective moda

215 of normal-appearing prostate tissue, benign prostatic hyperplasia, high-grade prostatic intraepithel

216 ogression stages, being detectable in benign prostatic hyperplasia, highly expressed in prostatic int

217 hic procedure that effectively treats benign prostatic hyperplasia; however, PAE-related patient radi

218 estosterone formation in the pathogenesis of prostatic hyperplasia in dogs and men.

219 n of Brm is causative for the development of prostatic hyperplasia in mice.

220 s and randomized controlled trials on benign prostatic hyperplasia in order to understand the applica

221 , we show that the loss of SSeCKS results in prostatic hyperplasia in the anterior and ventral lobes

222 ly undetectable in normal prostate or benign prostatic hyperplasia in vivo.

223 story of intraprostatic injection for benign prostatic hyperplasia including the most recent reports

224 Prostatic hyperplasia induced by both 15-LOX2 and 15-LOX

225 s is 1.1% and that for drugs to treat benign prostatic hyperplasia is 1-2%.

226 The surgical treatment of benign prostatic hyperplasia is a dynamic, evolving field.

227 Although benign prostatic hyperplasia is an important cause of these sym

228 btaining optimal outcomes in men with benign prostatic hyperplasia is careful patient selection and e

229 Benign prostatic hyperplasia is commonly treated with alpha-adr

230 of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentra

231 pplication in prostatic pathology and benign prostatic hyperplasia is not as clear.

232 ndard medical therapy for symptomatic benign prostatic hyperplasia is still alpha-blockers and 5alpha

233 prehensive clinical evaluation before benign prostatic hyperplasia is treated, if indicated.

234 t roles in myocardial hypertrophy and benign prostatic hyperplasia, little is known about acute effec

235 investigation modalities in men with benign prostatic hyperplasia/lower urinary tract symptoms (LUTS

236 r urinary tract symptom suggestive of benign prostatic hyperplasia (LUTS/BPH).

237 efore their place in the treatment of benign prostatic hyperplasia/LUTS can be properly assessed.

238 ic questions and counselling men with benign prostatic hyperplasia/LUTS.

239 Benign prostatic hyperplasia measures included development of m

240 n (PSCA)in normal urogenital tissues, benign prostatic hyperplasia (n = 21), prostatic intraepithelia

241 371 formalin-fixed blocks, including benign prostatic hyperplasia (n = 32) and primary tumors (n = 2

242 nation, suggesting an exacerbation of benign prostatic hyperplasia; no other subject reported adverse

243 (n = 48), hyperplasticepithelium from benign prostatic hyperplasia nodules (n = 22), PIA (n = 64), hi

244 The controls (benign prostatic hyperplasias, normal males, and normal females

245 d myopathic bladder dysfunction (from benign prostatic hyperplasia or posterior urethral valves) focu

246 ssed by epithelial cells derived from benign prostatic hyperplasia or prostate cancer; thus, fucosylt

247 tract symptom in men with symptomatic benign prostatic hyperplasia over alpha1-adrenergic antagonist

248 edical therapies for the treatment of benign prostatic hyperplasia over the past year, interest in an

249 rade prostate cancer when compared to benign prostatic hyperplasia (P<0.0001).

250 ents in the management of symptomatic benign prostatic hyperplasia, particularly the current role of

251 ore imaging studies than expected for benign prostatic hyperplasia patients in recent years, and seve

252 Prostatic hyperplasia predominantly involves the stromal

253 A 76-year-old male with prostatic hyperplasia presented with acute pyelonephriti

254 mmation was not related to LUTS or to benign prostatic hyperplasia progression.

255 histotripsy to preclinical models of benign prostatic hyperplasia, prostate cancer, renal masses, an

256 oup (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasterid

257 n 105 prostate samples, consisting of benign prostatic hyperplasia regions and malignant tumors, from

258 has been shown to reduce and control benign prostatic hyperplasia-related haematuria, although its v

259 nary retention or the requirement for benign prostatic hyperplasia-related surgery.

260 8 in patients with moderate to severe benign prostatic hyperplasia-related symptoms.

261 tic hyperplasia, because both PCa and benign prostatic hyperplasia release PSA into the serum.

262 ostatic artery embolization (PAE) for benign prostatic hyperplasia remains limited.

263 tate (TURP) has dominated symptomatic benign prostatic hyperplasia (s-BPH) surgical treatment for alm

264 hed nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.

265 Both proteins were present in benign prostatic hyperplasia samples.

266 ical therapy for LUTS associated with benign prostatic hyperplasia seems attractive and may have a po

267 Associations of prostatitis include benign prostatic hyperplasia, sexually transmitted disease, low

268 initial evaluation of a patient with benign prostatic hyperplasia should include a thorough history,

269 sk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatm

270 rtalized PrEC line established from a benign prostatic hyperplasia specimen (BPH-1), and in three pro

271 its expression is strongly reduced in benign prostatic hyperplasia suggesting that DAX-1 plays a role

272 In men with benign prostatic hyperplasia, terazosin was effective therapy,

273 and PUMA is comparable and higher in benign prostatic hyperplasia than in prostate cancer Gleason gr

274 lence of lower urinary tract symptoms/benign prostatic hyperplasia, the incidence of acute urinary re

275 for lower urinary tract symptoms and benign prostatic hyperplasia, the majority of the data availabl

276 assess the safety of histotripsy for benign prostatic hyperplasia therapy.

277 7Kip1 expression; acini in epithelial benign prostatic hyperplasia tissue contained more p27Kip1-nega

278 les and cultured PC cells compared to benign prostatic hyperplasia tissue samples and normal prostate

279 ithelial cells, derived from tumor or benign prostatic hyperplasia tissue, were studied using a three

280 ative basal cells than acini from non-benign prostatic hyperplasia tissue.

281 l compartment of normal prostatic and benign prostatic hyperplasia tissue.

282 is significantly higher than that in benign prostatic hyperplasia tissues, and PRMT5 expression corr

283 ly in advanced prostate cancer versus benign prostatic hyperplasia tissues.

284 prostate cancer, but not in normal or benign prostatic hyperplasia tissues.

285 ho had moderate-to-severe symptoms of benign prostatic hyperplasia to one year of treatment with saw

286 For benign prostatic hyperplasia, transperineal and transurethral i

287 otransferase (nine [6%] vs none), and benign prostatic hyperplasia (two [5%] vs none).

288 rogen receptor gene polymorphisms and benign prostatic hyperplasia was investigated among 510 men ran

289 y, the gold standard for treatment of benign prostatic hyperplasia was the electrocautery-based trans

290 rethral resection of the prostate for benign prostatic hyperplasia, we assessed serum, urine, and pro

291 ) mm(2)/sec) in glandular and stromal benign prostatic hyperplasia were 1.44 and 1.09, respectively.

292 rUGM+Rb+/+PRE tissue recombinants developed prostatic hyperplasia, whereas PRE in rUGM+Rb-/-PRE tiss

293 with bladder outlet obstruction from benign prostatic hyperplasia who are deemed high surgical risks

294 Benign prostatic hyperplasia with associated symptoms and morbi

295 The Stk11(CKO) mice develop prostatic hyperplasia with bladder outlet obstruction, m

296 for lower urinary tract symptoms and benign prostatic hyperplasia with either alpha adrenergic recep

297 as a safe and effective procedure for benign prostatic hyperplasia with good long-term results for lo

298 nimally invasive surgical therapy for benign prostatic hyperplasia with increased attention from the

299 ps were (i) histological diagnosis of benign prostatic hyperplasia with no evidence of cancer 'BPH',

300 rostate artery embolization (PAE) for benign prostatic hyperplasia with spherical particle polyvinyl